Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [²¹²Pb]Pb-AB001.

ABSTRACT: Targeted alpha therapy holds promise for treating advanced prostate cancer, but the interplay between prostate-specific membrane antigen (PSMA) expression, p53 status, and downstream cell fate remains poorly defined. This study evaluates the cytotoxic and cell cycle effects of the alpha-emitting radioligand [²¹²Pb]Pb-AB001 in prostate cancer cell lines with differing PSMA expression and p53 status: C4-2 (PSMA⁺/TP53-wild-type) and PC-3 PIP (PSMA⁺⁺⁺/ TP53-null). [²¹²Pb]Pb-AB001 significantly inhibited proliferation and clonogenic survival in both cell lines in an activity-dependent manner. At 95% clonogenic inhibition, both cell lines exhibited G2-phase arrest, S-phase suppression and reduced mitotic entry on day 1. At higher activities, PC-3 PIP c

SUBMITTER: Stenberg VY 

PROVIDER: S-EPMC12775525 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature